Page last updated: 2024-08-21

psilocybin and Behavior Disorders

psilocybin has been researched along with Behavior Disorders in 66 studies

Research

Studies (66)

Timeframe	Studies, this research(%)	All Research%
pre-1990	19 (28.79)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (1.52)	29.6817
2010's	12 (18.18)	24.3611
2020's	34 (51.52)	2.80

Authors

Authors	Studies
Basky, G	1
Hackl, B; Hilber, K; Koenig, X; Kubista, H; Todt, H	1
van Amsterdam, J; van den Brink, W	1
McClure-Begley, TD; Roth, BL	1
Argento, E; Christie, D; Mackay, L; Mocanu, V	1
Anderson, BT; Dourron, HM; Garcia-Romeu, A; Hendricks, PS; MacCarthy, S; Ortiz, CE; Sweat, NW	1
Carrillo, F; Cavanna, F; de la Fuente, L; García, AM; Janeckova, L; Kuchar, M; Muller, S; Pallavicini, C; Palmucci, M; Sanz, C; Tagliazucchi, E; Zamberlan, F	1
Gründer, G; Jungaberle, H; Schmidt, C; Wolff, M	1
da Costa, SC; Gold, M; Oesterle, T; Richelson, E; Rummans, TA	1
Kaypak, AC; Raz, A	1
Marks, M	1
Romach, MK; Sellers, EM	1
Davoudian, PA; Dibbs, M; Gregg, I; Jefferson, SJ; Kaye, AP; Kwan, AC; Liao, C; Pittenger, C; Sherwood, AM; Sprouse, JS; Wehrle, PH; Woodburn, SC; Wu, H	1
Kisely, S	1
Schindler, EAD	1
Ibrahim, IB; Straszek, SPV; Videbech, P	1
Hallgrimsdottir, K; Ketilsdottir, K; Kvaran, K; Olafsson, RP; Sigurdsson, E; Sigurdsson, EL	1
Wojtas, A	1
Fabregat-Safont, D; Gomez-Gomez, A; Madrid-Gambin, F; Mason, NL; Olesti, E; Pozo, OJ; Ramaekers, JG	1
Nutt, D	1
Carpenter, LL; Kalin, NH; McDonald, WM; Nemeroff, CB; Reiff, CM; Richman, EE; Rodriguez, CI; Widge, AS	1
Anderson, T; Dinh-Williams, LA; Hapke, E; Hui, K; Petranker, R; Rosenbaum, D; Weissman, C	1
Carhart-Harris, R; Erritzoe, D; Nutt, D	1
Greif, A; Šurkala, M	1
Hoskins, M; James, E; Robertshaw, TL; Sessa, B	1
Kuypers, KPC	1
Cha, DS; Chen-Li, D; El-Halabi, S; Gill, B; Gill, H; Ho, R; Lee, Y; Lipsitz, O; Majeed, A; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD	1
Chen, Z; Deole, G; Goldberg, SB; Ng, CW; Nicholas, CR; Raison, CL; Shechet, B	1
Aguilar-Valles, A; De Gregorio, D; Gobbi, G; Heifets, BD; Hibicke, M; Mitchell, J; Preller, KH	1
Breeksema, JJ; Koolen, MHB; Schoevers, RA; Somers, M	1
Cusimano, J; Hosanagar, A; Radhakrishnan, R	2
Forsyth, A; Lumley, T; Muthukumaraswamy, SD	1
Carhart-Harris, RL; Douglass, H; Erritzoe, D; Johnson, MW; Kettner, H; Teixeira, PJ; Timmermann, C; Watts, R	1
Ali, A; Gordon, L; Grant, J; Lowe, H; Ngwa, W; Steele, B; Toyang, N; Valentine, H	1
Carhart-Harris, RL; Goodwin, GM	1
Griffiths, RR; Johnson, MW	1
Larsen, JK	1
Gallinat, J; Hermle, L; Jungaberle, H; Majić, T; Schmidt, TT; Zeuch, A	1
Sessa, B	1
Heifets, BD; Malenka, RC	1
Brugger, S; Carhart-Harris, RL; Nutt, DJ; Stone, JM	1
Johansen, PØ; Krebs, TS	1
Brewerton, TD; Grob, CS; Mithoefer, MC	1
Johnson, MW; Nichols, CD; Nichols, DE	1
Barbee, G; Barry, J; Berry-Cabán, C; Borys, D; Salyer, S; Ward, J	1
Griffths, RR; Grob, CS	1
HEIMANN, H	2
JAROS, O; KOVARIK, J; SERCL, M	1
GROF, S; VITEK, V; VOJTECHOVSKY, M	1
KRISTENSEN, KK	1
BUOSO, GM; RABASSINI, A; SOGLIANI, G	1
LINGL, FA; TOLAN, EJ	1
CANCRINI, L; D AGOSTINO, E; REDA, GC; VELLA, G	1
LEUNER, H	2
Johnsen, G	1
Glancy, G; Hall, D; Hyde, C; Omerod, P; Taylor, GS	1
Kochansky, GE; Lieff, J; Salzman, C; Shader, RI	1
Rysánek, K	1
Fischer, R; Scheib, J	1
Jorgensen, F	1
Endo, M; Kato, H; Onodera, I; Saito, Y; Yamazaki, A	1
Archer, RC; Fischer, R; Griffin, F; Jastram, PS; Zinsmeister, SC	1
Flores, JR	1

Reviews

32 review(s) available for psilocybin and Behavior Disorders

Article	Year
The therapeutic potential of psilocybin: a systematic review. Expert opinion on drug safety, 2022, Volume: 21, Issue:6 Topics: Double-Blind Method; Hallucinogens; Humans; Mental Disorders; Psilocybin; Randomized Controlled Trials as Topic	2022
The promises and perils of psychedelic pharmacology for psychiatry. Nature reviews. Drug discovery, 2022, Volume: 21, Issue:6 Topics: Hallucinogens; Humans; Lysergic Acid Diethylamide; Mental Disorders; Psilocybin; Psychiatry; Receptor, Serotonin, 5-HT2A	2022
Special considerations for evaluating psilocybin-facilitated psychotherapy in vulnerable populations. Neuropharmacology, 2022, 08-15, Volume: 214 Topics: Hallucinogens; Humans; Mental Disorders; Psilocybin; Psychotherapy; Vulnerable Populations	2022
Psychedelic drugs for psychiatric disorders. Journal of the neurological sciences, 2022, 09-15, Volume: 440 Topics: Alcoholism; Hallucinogens; Humans; Lysergic Acid Diethylamide; Mental Disorders; Psilocybin	2022
Macrodosing to microdosing with psychedelics: Clinical, social, and cultural perspectives. Transcultural psychiatry, 2022, Volume: 59, Issue:5 Topics: Hallucinogens; Humans; Lysergic Acid Diethylamide; Mental Disorders; N,N-Dimethyltryptamine; Psilocybin	2022
The varieties of psychedelic law. Neuropharmacology, 2023, 03-15, Volume: 226 Topics: Adult; Hallucinogens; Humans; Mental Disorders; Psilocybin	2023
Psychedelics: Science sabotaged by Social Media. Neuropharmacology, 2023, 04-01, Volume: 227 Topics: Hallucinogens; Humans; Lysergic Acid Diethylamide; Mental Disorders; Psilocybin; Social Media	2023
The Potential of Psychedelics for the Treatment of Episodic Migraine. Current pain and headache reports, 2023, Volume: 27, Issue:9 Topics: Cluster Headache; Hallucinogens; Humans; Mental Disorders; Migraine Disorders; Psilocybin	2023
Ugeskrift for laeger, 2023, Aug-07, Volume: 185, Issue:32 Topics: Escitalopram; Hallucinogens; Humans; Ketamine; Mental Disorders; Psilocybin	2023
The possible place for psychedelics in pharmacotherapy of mental disorders. Pharmacological reports : PR, 2023, Volume: 75, Issue:6 Topics: Antidepressive Agents; Hallucinogens; Humans; Ketamine; Mental Disorders; Psilocybin; Serotonin	2023
Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023, Dec-31, Volume: 169 Topics: Hallucinogens; Humans; Lysergic Acid Diethylamide; Mental Disorders; N,N-Dimethyltryptamine; Psilocybin	2023
Psychedelic drugs-a new era in psychiatry? . Dialogues in clinical neuroscience, 2019, Volume: 21, Issue:2 Topics: Hallucinogens; Humans; Ketamine; Lysergic Acid Diethylamide; Mental Disorders; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Psychiatry	2019
Psychedelics and Psychedelic-Assisted Psychotherapy. The American journal of psychiatry, 2020, 05-01, Volume: 177, Issue:5 Topics: Evidence-Based Practice; Hallucinogens; Humans; Lysergic Acid Diethylamide; Mental Disorders; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Psychotherapy	2020
Compassionate use of psychedelics. Medicine, health care, and philosophy, 2020, Volume: 23, Issue:3 Topics: Chronic Disease; Compassionate Use Trials; Hallucinogens; Humans; Mental Disorders; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Psychotherapy; Terminal Care	2020
Psilocybin occasioned mystical-type experiences. Human psychopharmacology, 2020, Volume: 35, Issue:5 Topics: Hallucinogens; Humans; Mental Disorders; Mysticism; Psilocybin; Psychotherapy; Research Design	2020
The emerging role of psilocybin and MDMA in the treatment of mental illness. Expert review of neurotherapeutics, 2020, Volume: 20, Issue:12 Topics: Hallucinogens; Humans; Mental Disorders; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin	2020
Post-acute psychological effects of classical serotonergic psychedelics: a systematic review and meta-analysis. Psychological medicine, 2020, Volume: 50, Issue:16 Topics: Banisteriopsis; Evidence-Based Practice; Hallucinogens; Humans; Lysergic Acid Diethylamide; Mental Disorders; Psilocybin; Randomized Controlled Trials as Topic	2020
Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2021, 02-03, Volume: 41, Issue:5 Topics: Animals; Brain; Hallucinogens; Humans; Ketamine; Lysergic Acid Diethylamide; Mental Disorders; Mental Health; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Randomized Controlled Trials as Topic	2021
[Treatment with psilocybin: applications for patients with psychiatric disorders]. Nederlands tijdschrift voor geneeskunde, 2021, 01-21, Volume: 165 Topics: Adult; Clinical Trials as Topic; Female; Hallucinogens; Humans; Male; Mental Disorders; Psilocybin; Treatment Outcome	2021
Therapeutic Potential of Psychedelics in the Treatment of Psychiatric Disorders, Part 1: Psychopharmacology and Neurobiological Effects. The Journal of clinical psychiatry, 2021, 02-23, Volume: 82, Issue:2 Topics: Banisteriopsis; Hallucinogens; Humans; Lysergic Acid Diethylamide; Mental Disorders; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Psychopharmacology	2021
Therapeutic Potential of Psychedelics in Treatment of Psychiatric Disorders, Part 2: Review of the Evidence. The Journal of clinical psychiatry, 2021, 02-23, Volume: 82, Issue:3 Topics: Banisteriopsis; Hallucinogens; Humans; Lysergic Acid Diethylamide; Mental Disorders; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin	2021
Blinding and expectancy confounds in psychedelic randomized controlled trials. Expert review of clinical pharmacology, 2021, Volume: 14, Issue:9 Topics: Confounding Factors, Epidemiologic; Hallucinogens; Humans; Ketamine; Lysergic Acid Diethylamide; Mental Disorders; Psilocybin; Randomized Controlled Trials as Topic; Research Design	2021
Psychedelics and health behaviour change. Journal of psychopharmacology (Oxford, England), 2022, Volume: 36, Issue:1 Topics: Hallucinogens; Health Behavior; Healthy Lifestyle; Humans; Mental Disorders; Mental Health; Psilocybin	2022
The Therapeutic Potential of Psilocybin. Molecules (Basel, Switzerland), 2021, May-15, Volume: 26, Issue:10 Topics: Biomedical Research; Clinical Studies as Topic; Hallucinogens; Humans; Mental Disorders; Molecular Structure; Neoplasms; Psilocybin	2021
The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2017, Volume: 42, Issue:11 Topics: Animals; Hallucinogens; History, 20th Century; History, 21st Century; Humans; Mental Disorders; Psilocybin	2017
Potential Therapeutic Effects of Psilocybin. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2017, Volume: 14, Issue:3 Topics: Hallucinogens; Humans; Mental Disorders; Psilocybin	2017
[Psychotherapy with Adjuvant use of Serotonergic Psychoactive Substances: Possibilities and Challenges]. Fortschritte der Neurologie-Psychiatrie, 2017, Volume: 85, Issue:7 Topics: Combined Modality Therapy; Hallucinogens; Humans; Lysergic Acid Diethylamide; Mental Disorders; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Psychotherapy; Serotonin Agents; Treatment Outcome	2017
The 21st century psychedelic renaissance: heroic steps forward on the back of an elephant. Psychopharmacology, 2018, Volume: 235, Issue:2 Topics: Animals; Data Collection; Emotions; Forecasting; Hallucinogens; Humans; Mental Disorders; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Stress Disorders, Post-Traumatic	2018
Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. The lancet. Psychiatry, 2016, Volume: 3, Issue:5 Topics: Humans; Mental Disorders; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Psychopharmacology; Psychotropic Drugs; Randomized Controlled Trials as Topic	2016
Psychedelics as Medicines: An Emerging New Paradigm. Clinical pharmacology and therapeutics, 2017, Volume: 101, Issue:2 Topics: Anxiety; Brain; Clinical Trials as Topic; Depression; Dose-Response Relationship, Drug; Hallucinogens; Humans; Inflammation; Inflammation Mediators; Lysergic Acid Diethylamide; Mental Disorders; Mind-Body Therapies; Obsessive-Compulsive Disorder; Psilocybin; Psychotherapy; Receptor, Serotonin, 5-HT2A; Serotonin 5-HT2 Receptor Agonists; Severity of Illness Index; Substance-Related Disorders	2017
[CLINICAL AND PSYCHOPATHOLOGICAL STUDY OF PSILOCYBIN]. Rivista sperimentale di freniatria e medicina legale delle alienazioni mentali, 1964, Mar-31, Volume: 88 Topics: Antisocial Personality Disorder; Asthenia; Blood Pressure; Consciousness; Depression; Depressive Disorder; Electroencephalography; Hallucinations; Hallucinogens; Hearing Disorders; Indoles; Mental Disorders; Mental Processes; Movement Disorders; Nausea; Pharmacology; Psilocybin; Psychopathology; Salivary Glands; Sweating; Toxicology; Vestibule, Labyrinth; Visual Perception	1964
[Relation of monoamines to mental disorders]. Activitas nervosa superior, 1970, Volume: 12, Issue:2 Topics: Amines; Animals; Bipolar Disorder; Catecholamines; Central Nervous System; Depression; Dihydroxyphenylalanine; Dopamine; Epinephrine; Hallucinogens; Humans; Lysergic Acid Diethylamide; Mental Disorders; Methylation; Monoamine Oxidase Inhibitors; Phenethylamines; Psilocybin; Reserpine; Schizophrenia; Serotonin; Tryptamines	1970

Other Studies

34 other study(ies) available for psilocybin and Behavior Disorders

Article	Year
Policy in focus: Is psilocybin the next cannabis? CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2021, 11-15, Volume: 193, Issue:45 Topics: Canada; Combined Modality Therapy; Hallucinogens; Health Policy; Humans; Medical Marijuana; Mental Disorders; Psilocybin; Psychotherapy; United States	2021
Psilocybin Therapy of Psychiatric Disorders Is Not Hampered by hERG Potassium Channel-Mediated Cardiotoxicity. The international journal of neuropsychopharmacology, 2022, 04-19, Volume: 25, Issue:4 Topics: Cardiotoxicity; Hallucinogens; Humans; Mental Disorders; Potassium Channels; Psilocybin	2022
Safety considerations in the evolving legal landscape of psychedelic-assisted psychotherapy. Substance abuse treatment, prevention, and policy, 2022, 05-14, Volume: 17, Issue:1 Topics: Canada; Hallucinogens; Humans; Mental Disorders; Psilocybin; Psychotherapy	2022
Natural language signatures of psilocybin microdosing. Psychopharmacology, 2022, Volume: 239, Issue:9 Topics: Adult; Creativity; Double-Blind Method; Female; Hallucinogens; Humans; Language; Male; Mental Disorders; Psilocybin	2022
[Attitudes of Mental Health Experts Towards Psilocybin]. Fortschritte der Neurologie-Psychiatrie, 2023, Volume: 91, Issue:3 Topics: Attitude; Hallucinogens; Humans; Mental Disorders; Mental Health; Psilocybin	2023
5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2023, Volume: 48, Issue:9 Topics: Animals; Hallucinogens; Instinct; Mental Disorders; Methoxydimethyltryptamines; Mice; Psilocybin	2023
The down-scheduling of MDMA and psilocybin(e): Too fast and too soon. The Australian and New Zealand journal of psychiatry, 2023, Volume: 57, Issue:7 Topics: Hallucinogens; Humans; Mental Disorders; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin	2023
[Psychedelics and treatment of mental disorders: A survey of attitudes and knowledge among psychiatrists, general practitioners and psychologists in Iceland]. Laeknabladid, 2023, Volume: 109, Issue:11 Topics: General Practitioners; Hallucinogens; Humans; Iceland; Mental Disorders; Psilocybin; Psychiatry; Surveys and Questionnaires	2023
Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities. Journal of psychopharmacology (Oxford, England), 2020, Volume: 34, Issue:6 Topics: Adolescent; Adult; Cross-Sectional Studies; Dose-Response Relationship, Drug; Female; Hallucinogens; Humans; Lysergic Acid Diethylamide; Male; Mental Disorders; Psilocybin; Substance-Related Disorders; Surveys and Questionnaires; Young Adult	2020
Psychedelic Psychiatry's Brave New World. Cell, 2020, 04-02, Volume: 181, Issue:1 Topics: Hallucinogens; Humans; Mental Disorders; Neuropharmacology; Psilocybin; Psychiatry; Serotonin 5-HT2 Receptor Agonists	2020
[Microdosing with psychedelics: what do we know?] Tijdschrift voor psychiatrie, 2020, Volume: 62, Issue:8 Topics: Hallucinogens; Humans; Mental Disorders; Mental Health; Psilocybin; Retrospective Studies	2020
LSD treatment in Scandinavia: emphasizing indications and short-term treatment outcomes of 151 patients in Denmark. Nordic journal of psychiatry, 2017, Volume: 71, Issue:7 Topics: Adult; Denmark; Female; Follow-Up Studies; Humans; Lysergic Acid Diethylamide; Male; Mental Disorders; Psilocybin; Retrospective Studies; Risk	2017
Disruptive Psychopharmacology. JAMA psychiatry, 2019, 08-01, Volume: 76, Issue:8 Topics: Consciousness; Humans; Ketamine; Mental Disorders; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Psychopharmacology; Psychotropic Drugs	2019
Psychiatry's next top model: cause for a re-think on drug models of psychosis and other psychiatric disorders. Journal of psychopharmacology (Oxford, England), 2013, Volume: 27, Issue:9 Topics: Amphetamine; Cannabis; Drug Users; Ethanol; Female; Humans; Ketamine; Male; Mental Disorders; Pilot Projects; Psilocybin; Psychiatry; Psychoses, Substance-Induced	2013
Psychedelics and mental health: a population study. PloS one, 2013, Volume: 8, Issue:8 Topics: Adolescent; Adult; Data Collection; Female; Hallucinogens; Humans; Lysergic Acid Diethylamide; Male; Mental Disorders; Mental Health; Mescaline; Middle Aged; Odds Ratio; Psilocybin; Risk Factors; United States	2013
Analysis of mushroom exposures in Texas requiring hospitalization, 2005-2006. Journal of medical toxicology : official journal of the American College of Medical Toxicology, 2009, Volume: 5, Issue:2 Topics: Abdominal Pain; Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Diarrhea; Female; Hallucinogens; Hospitalization; Humans; Infant; Male; Mental Disorders; Middle Aged; Mushroom Poisoning; Nausea; Poison Control Centers; Psilocybin; Retrospective Studies; Texas; Vomiting; Young Adult	2009
Hallucinogens as medicine. Scientific American, 2010, Volume: 303, Issue:6 Topics: Female; Hallucinogens; Humans; Mental Disorders; Middle Aged; Psilocybin; Psychopharmacology	2010
[Expressive phenomenology of model psychoses (psilocybin). Comparison with self-description and psychic deficiency of performance]. Psychiatria et neurologia, 1961, Volume: 141 Topics: Hallucinogens; Indoles; Mental Disorders; Psilocybin; Psychotic Disorders	1961
[On the treatment of therapy-resistant neuroses with model psychoses (psilocybin)]. Schweizer Archiv fur Neurologie, Neurochirurgie und Psychiatrie = Archives suisses de neurologie, neurochirurgie et de psychiatrie, 1962, Volume: 89 Topics: Hallucinogens; Mental Disorders; Neurotic Disorders; Psilocybin; Psychotic Disorders	1962
[Clinical experiences with psilocybin Sandoz (CY 39 Sandoz)]. Sbornik vedeckych praci Lekarske fakulty Karlovy university v Hradci Kralove, 1961, Volume: 4 Topics: Electroconvulsive Therapy; Hallucinogens; Indoles; Mental Disorders; Psilocybin; Psychosurgery; Psychotherapy	1961
[Serotonin metabolism in experimental psilocybin psychosis]. Activitas nervosa superior, 1961, Volume: 3 Topics: Biochemical Phenomena; Hallucinogens; Indoles; Mental Disorders; Psilocybin; Psychotic Disorders; Serotonin	1961
[CLINICAL EXPERIENCES WITH PSILOCYBIN]. Nordisk psykiatrisk tidsskrift. Nordic journal of psychiatry, 1963, Volume: 17 Topics: Hallucinogens; Humans; Mental Disorders; Psilocybin	1963
[PSYCHOMIMETIC SUBSTANCES. (CONTRIBUTION TO THE CLINICAL PSYCHOPATHOLOGICAL STUDY OF PSILOCYBIN)]. Rivista sperimentale di freniatria e medicina legale delle alienazioni mentali, 1963, Sep-30, Volume: 87 Topics: Biomedical Research; Diagnosis; Hallucinogens; Indoles; Mental Disorders; Psilocybin; Psychopathology; Psychopharmacology; Psychotherapy	1963
"MODEL PSYCHOSIS" PRODUCED BY INHALATION OF GASOLINE FUMES. The American journal of psychiatry, 1964, Volume: 120 Topics: Adolescent; Gasoline; Hallucinations; Hallucinogens; Humans; Lysergic Acid Diethylamide; Mental Disorders; Mescaline; Petroleum; Projective Techniques; Psilocybin; Psychophysiology; Psychoses, Substance-Induced; Psychotic Disorders; Toxicology	1964
[FUNDAMENTALS OF A CONDITIONAL-GENETIC PSYCHOPATHOLOGY AS EXEMPLIFIED BY EXPERIMENTAL PSYCHOSIS]. Der Nervenarzt, 1963, Volume: 34 Topics: Hallucinogens; Lysergic Acid Diethylamide; Mental Disorders; Mescaline; Neurotic Disorders; Psilocybin; Psychopathology; Psychotherapy; Psychotic Disorders; Toxicology	1963
THREE YEARS' EXPERIENCE WITH THE USE OF LSD AS AN AID IN PSYCHOTHERAPY. Acta psychiatrica Scandinavica, 1964, Volume: 39, Issue:S180 Topics: Drug Therapy; Hallucinogens; Humans; Lysergic Acid Diethylamide; Mental Disorders; Neurotic Disorders; Prognosis; Psilocybin; Psychoanalytic Therapy; Psychotherapy; Psychotic Disorders	1964
Abuse of indigenous psilocybin mushrooms: a new fashion and some psychiatric complications. The British journal of psychiatry : the journal of mental science, 1978, Volume: 132 Topics: Adult; Basidiomycota; Hallucinations; Humans; Male; Mental Disorders; Psilocybin; Substance-Related Disorders	1978
The psychology of hallucinogenic drug discontinuers. The American journal of psychiatry, 1972, Volume: 129, Issue:6 Topics: Adult; Anxiety; Depression; Female; Gambling; Hallucinogens; Humans; Lysergic Acid Diethylamide; Male; Mental Disorders; Mescaline; MMPI; Personality; Psilocybin; Psychological Tests; Substance-Related Disorders	1972
Creative performance and the hallucinogenic drug-induced creative experience or one man's brain-damage is another's creativity. Confinia psychiatrica. Borderland of psychiatry. Grenzgebiete der Psychiatrie. Les Confins de la psychiatrie, 1971, Volume: 14, Issue:3 Topics: Affect; Art; Body Image; Brain Damage, Chronic; Creativity; Dreams; Esthetics; Female; Field Dependence-Independence; Hallucinations; Handwriting; Humans; Male; Mental Disorders; Psilocybin; Psychological Tests; Self Concept; Social Perception	1971
Abuse of psychotomimetics. Acta psychiatrica Scandinavica. Supplementum, 1968, Volume: 203 Topics: Adolescent; Adult; Cannabis; Crime; Denmark; Educational Status; Family; Family Characteristics; Female; Hallucinogens; Humans; Lysergic Acid Diethylamide; Male; Mental Disorders; Occupations; Psilocybin; Sex Factors; Social Class; Social Problems; Substance-Related Disorders	1968
[Change in the concentration of 17-OHCS in the blood upon administration of psilocybine]. Horumon to rinsho. Clinical endocrinology, 1968, Volume: 16, Issue:3 Topics: 17-Hydroxycorticosteroids; Adult; Animals; Female; Humans; Male; Mental Disorders; Psilocybin; Rabbits	1968
[Is the use of LSD-25 in experimental psychiatry and psychotherapy today still justifiable?]. Der Nervenarzt, 1968, Volume: 39, Issue:8 Topics: Chemical Phenomena; Chemistry; Humans; Lysergic Acid Diethylamide; Mental Disorders; Psilocybin; Psychopharmacology; Psychotherapy	1968
Weber ratio in gustatory chemoreception; an indicator of systemic (drug) reactivity. Nature, 1965, Sep-04, Volume: 207, Issue:5001 Topics: Adult; Female; Humans; Male; Mental Disorders; Models, Theoretical; Psilocybin; Sensory Receptor Cells; Sweetening Agents; Taste; Trifluoperazine	1965
[Experimental psychosyndrome with psilocybine]. Revista de neuro-psiquiatria, 1966, Volume: 29, Issue:1 Topics: Adult; Emotions; Humans; Male; Mental Disorders; Perception; Psilocybin	1966